Company Directory

Global viral vector CDMO for cell and gene therapy

Oxford Biomedica (OXB) is a global contract development and manufacturing organisation specialising in viral vectors for cell and gene therapy. The company provides lentiviral, adeno-associated virus (AAV), and adenoviral vector development and manufacturing services from early-stage process development through to commercial-scale GMP manufacture. OXB is headquartered in Oxford and operates manufacturing sites across Oxfordshire, France, and the United States.

Global biopharma with UK manufacturing, commercial and clinical operations

MSD is a global biopharmaceutical company discovering, developing, manufacturing and marketing medicines and vaccines across oncology, infectious disease, immunology, cardiometabolic disease and animal health. Its UK operations span pharmaceutical manufacturing at Cramlington, Northumberland, which supplies medicines into the Merck global network, alongside commercial and clinical development functions headquartered at Moorgate, London, and an Animal Health division based in Milton Keynes. MSD conducts approximately 150 clinical studies in the UK annually.

Automated bioreactor platform for cell and gene therapy manufacturing

microfluidX is a UK instruments company developing automated bioprocessing platforms for cell and gene therapy research and manufacturing. Its core product is a microfluidics-based bioreactor system designed for parallel cell culture process development and scalable cell expansion. The platform integrates online process analytical tools and data analytics and is intended to support the development and manufacture of autologous cell and gene therapies from research scale through to clinical and commercial production.

Silica encapsulation platform eliminating cold chain for biologics

EnsiliTech is a biotechnology company developing ensilication, a patented platform technology that encases vaccines, antibodies, and other biologics within a silica matrix to render them thermally stable without refrigeration. The technology is applicable to existing and new biopharmaceutical formulations, enabling storage and transport at temperatures up to 50°C. EnsiliTech is developing applications across vaccines and monoclonal antibody therapeutics, with partners including the Centre for Process Innovation.

Next-generation lateral CAR-T therapies for refractory solid tumours

Leucid Bio Ltd is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for hard-to-treat solid tumours. Founded on over two decades of King's College London research, the platform redesigns the CAR signalling architecture to enhance T-cell potency, persistence, and tumour infiltration. Lead asset LEU011 targets NKG2D stress ligands expressed on over 80% of human tumours and is being evaluated in the Phase I/IIa AERIAL multi-centre dose-escalation trial, manufactured at Great Ormond Street Hospital's GMP facilities.

Pharmaceutical formulation development and clinical manufacturing services

SGS Quay Pharma is a contract development and manufacturing organisation providing formulation development, analytical services, and clinical trial manufacturing for pharmaceutical and biotechnology companies. The company specialises in dosage form design for APIs with challenging solubility and bioavailability profiles, and in modified and controlled release formulations. Operating from a MHRA and FDA-approved facility in North Wales, it supports clients from preclinical stage through to Phase III and commercial manufacture.

Specialist CRO for inhaled and nasal drug product development

Nanopharm is a contract research organisation specialising in the development of orally inhaled and nasal drug products, providing formulation development, materials characterisation, analytical testing, and in vitro and in silico modelling services to pharmaceutical and biotechnology clients. The company supports development from preclinical through to cGMP clinical stages, including regulatory strategy. Its proprietary platform enables bioequivalence demonstration for generic inhalation products without comparative clinical endpoint studies.

Robotic automation platform for scalable cell therapy manufacturing

Cellular Origins is a biotechnology company developing robotic automation systems for the industrial-scale manufacture of cell therapies. Its platform uses mobile robotics and automated sterile fluidic interconnection to link existing bioprocess instruments into fully automated, GMP-compliant manufacturing workflows. The platform is designed to scale production without requiring therapy redevelopment or process change. Cellular Origins partners with cell therapy developers and equipment manufacturers including Cytiva, Fresenius Kabi and Thermo Fisher Scientific.

Lyophilisation equipment, CDMO services, and freeze-drying expertise

Biopharma Group is a contract development and manufacturing organisation and capital equipment supplier specialising in lyophilisation and liquid formulation technologies. The company serves pharmaceutical, biotechnology, and diagnostics clients across two divisions: an equipment sales and technical service division supplying freeze dryers, aseptic fill-finish lines, and cryogenic storage systems; and a CDMO division providing formulation development, cycle development, and GMP and non-GMP contract manufacturing.

Ex-vivo organ perfusion services for preclinical drug evaluation

Pebble Bio is a contract research organisation providing ex-vivo organ and tissue perfusion services as an alternative to large animal experimentation. Using living organ systems maintained under physiological conditions, the company evaluates the safety, efficacy, and pharmacology of novel therapeutics, biomedical materials, and medical devices. Services are structured as fee-per-project packages supporting assets from early-stage evaluation through to regulatory submission.

Biopharmaceutical group distributing and developing cannabis-based medicines

GROW Group is a biopharmaceutical company focused exclusively on cannabis-based medicines, operating through complementary distribution and research divisions. Its UK distribution arm, Grow Group UK, is a licensed GMP specials manufacturer supplying prescribed cannabinoid medicines to patients via specialist physicians. Its R&D division, GROW Biotech, develops cannabinoid extraction, purification, and delivery technologies at its Harpenden laboratory. The group serves patients, prescribers, and international cannabis producers, and holds patents on novel cannabinoid processing methods.

Recombinant antibody sequencing, engineering and manufacturing services

Absolute Antibody specialises in recombinant antibody technology, offering sequencing, engineering and production services alongside a catalogue of recombinant antibodies and Fc fusion proteins in a range of formats. The company's ISO 9001:2015-certified manufacturing facility serves pharmaceutical, biotechnology, diagnostics and academic customers across more than 65 countries. Absolute Antibody operates as part of Vector Laboratories following a 2024 merger, and retains its independent brand and UK manufacturing operations.